120 related articles for article (PubMed ID: 21046104)
21. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
Kaufman GP; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Lust JA; Russell S; Go RS; Hwa YL; Kyle RA; Rajkumar SV; Kumar SK
Leukemia; 2016 Mar; 30(3):633-9. PubMed ID: 26487275
[TBL] [Abstract][Full Text] [Related]
22. NFKB1 common variants and PPP1R13L and CD3EAP in relation to lung cancer risk in a Chinese population.
Yin J; Yin M; Vogel U; Wu Y; Yao T; Cheng Y; Sun Z; Hou W; Wang C
Gene; 2015 Aug; 567(1):31-5. PubMed ID: 25917613
[TBL] [Abstract][Full Text] [Related]
23. A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study.
Hansen RD; Sørensen M; Tjønneland A; Overvad K; Wallin H; Raaschou-Nielsen O; Vogel U
BMC Cancer; 2008 Feb; 8():54. PubMed ID: 18289367
[TBL] [Abstract][Full Text] [Related]
24. Different splicing isoforms of ERCC1 affect the expression of its overlapping genes CD3EAP and PPP1R13L, and indicate a potential application in non-small cell lung cancer treatment.
Zhang G; Xue P; Cui S; Yu T; Xiao M; Zhang Q; Cai Y; Jin C; Yang J; Wu S; Lu X
Int J Oncol; 2018 Jun; 52(6):2155-2165. PubMed ID: 29620255
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
El-Ghammaz AM; Abdelwahed E
Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
[TBL] [Abstract][Full Text] [Related]
26. Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival.
Andersen NF; Vogel U; Klausen TW; Gimsing P; Gregersen H; Abildgaard N; Vangsted AJ
Eur J Haematol; 2015 Jan; 94(1):60-6. PubMed ID: 24954766
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach.
Horvath N; Hahn U; Joshua D; Dyson P; Gibson J; Stevens J; Rawling T; Barrow L; Brown R; Stephens S; Gower G; Norman J; Mills B; To LB
Intern Med J; 2004 Apr; 34(4):167-75. PubMed ID: 15086696
[TBL] [Abstract][Full Text] [Related]
28. Genetic variations in multiple myeloma II: association with effect of treatment.
Vangsted A; Klausen TW; Vogel U
Eur J Haematol; 2012 Feb; 88(2):93-117. PubMed ID: 21883476
[TBL] [Abstract][Full Text] [Related]
29. Haplotype frequencies in a sub-region of chromosome 19q13.3, related to risk and prognosis of cancer, differ dramatically between ethnic groups.
Schierup MH; Mailund T; Li H; Wang J; Tjønneland A; Vogel U; Bolund L; Nexø BA
BMC Med Genet; 2009 Mar; 10():20. PubMed ID: 19257887
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
31. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
[TBL] [Abstract][Full Text] [Related]
32. TP53 common variants and interaction with PPP1R13L and CD3EAP SNPs and lung cancer risk and smoking behavior in a Chinese population.
Yin J; Hou W; Vogel U; Li X; Ma Y; Wang C; Wang H; Sun Z
Biomed J; 2022 Feb; 45(1):169-178. PubMed ID: 35351459
[TBL] [Abstract][Full Text] [Related]
33. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
34. Specific correlation between the major chromosome 10q26 haplotype conferring risk for age-related macular degeneration and the expression of
Liao SM; Zheng W; Zhu J; Lewis CA; Delgado O; Crowley MA; Buchanan NM; Jaffee BD; Dryja TP
Mol Vis; 2017; 23():318-333. PubMed ID: 28659708
[TBL] [Abstract][Full Text] [Related]
35. Correlation of MicroRNA 17-92 Cluster Host Gene (MIR17HG) Polymorphisms With Susceptibility and Prognosis for Multiple Myeloma.
Wu H; Huang T; Ye Z; Fu X; Hu K; Yang X
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e359-e366. PubMed ID: 31029648
[TBL] [Abstract][Full Text] [Related]
36. Association of chromosome 19q13.2-3 haplotypes with basal cell carcinoma: tentative delineation of an involved region using data for single nucleotide polymorphisms in two cohorts.
Rockenbauer E; Bendixen MH; Bukowy Z; Yin J; Jacobsen NR; Hedayati M; Vogel U; Grossman L; Bolund L; Nexø BA
Carcinogenesis; 2002 Jul; 23(7):1149-53. PubMed ID: 12117772
[TBL] [Abstract][Full Text] [Related]
37. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.
Moreau P; Giralt SA
Leuk Res; 2012 Nov; 36 Suppl 1():S13-8. PubMed ID: 23176719
[TBL] [Abstract][Full Text] [Related]
38. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
Offidani M; Leoni P; Corvatta L; Polloni C; Gentili S; Savini A; Alesiani F; Brunori M; Catarini M; Visani G; Samori A; Burattini M; Centurioni R; Montanari M; Fraticelli P; Ruggieri M; Falcioni S; Galieni P
Eur J Haematol; 2010 Jun; 84(6):474-83. PubMed ID: 20331733
[TBL] [Abstract][Full Text] [Related]
39. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
[TBL] [Abstract][Full Text] [Related]
40. The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT.
Vangsted AJ; Klausen TW; Ruminski W; Gimsing P; Andersen NF; Gang AO; Abildgaard N; Knudsen LM; Nielsen JL; Gregersen H; Vogel U
Bone Marrow Transplant; 2009 Apr; 43(7):539-45. PubMed ID: 18997828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
